AU2003232751A1 - Immunoglobulin conjugates of autoantigens and their use in the prevention of disease - Google Patents

Immunoglobulin conjugates of autoantigens and their use in the prevention of disease Download PDF

Info

Publication number
AU2003232751A1
AU2003232751A1 AU2003232751A AU2003232751A AU2003232751A1 AU 2003232751 A1 AU2003232751 A1 AU 2003232751A1 AU 2003232751 A AU2003232751 A AU 2003232751A AU 2003232751 A AU2003232751 A AU 2003232751A AU 2003232751 A1 AU2003232751 A1 AU 2003232751A1
Authority
AU
Australia
Prior art keywords
peptide
conjugate
diabetes
insulin
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003232751A
Other languages
English (en)
Inventor
Christian Boitard
Yves Borel
Werner Schlegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tolerogen Ltd
Original Assignee
Tolerogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolerogen Ltd filed Critical Tolerogen Ltd
Publication of AU2003232751A1 publication Critical patent/AU2003232751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003232751A 2003-05-12 2003-05-12 Immunoglobulin conjugates of autoantigens and their use in the prevention of disease Abandoned AU2003232751A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/004922 WO2004098645A1 (fr) 2003-05-12 2003-05-12 Conjugues immunoglobuline d'autoantigenes et utilisation de ceux-ci dans la prevention de maladies

Publications (1)

Publication Number Publication Date
AU2003232751A1 true AU2003232751A1 (en) 2004-11-26

Family

ID=33426937

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003232751A Abandoned AU2003232751A1 (en) 2003-05-12 2003-05-12 Immunoglobulin conjugates of autoantigens and their use in the prevention of disease

Country Status (3)

Country Link
AU (1) AU2003232751A1 (fr)
CA (1) CA2524615A1 (fr)
WO (1) WO2004098645A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EP3909603A1 (fr) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Agents thérapeutiques de glycociblage
WO2018232176A1 (fr) 2017-06-16 2018-12-20 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
BR112023023479A2 (pt) * 2021-05-10 2024-01-30 Nykode Therapeutics ASA Construção indutora de tolerância, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteínas dimérica e multimérica, composição farmacêutica, e, métodos para preparar a composição farmacêutica, para tratar um indivíduo que sofre de uma condição envolvendo reações imunes indesejáveis e para aperfeiçoar a tolerância a um antígeno próprio, um alérgeno, um aloantígeno ou um xenoantígeno

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504136A4 (en) * 1989-12-07 1994-06-29 Blood Res Center Tolerogenic immunoglobulin-protein conjugates
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
DE69627820T2 (de) * 1995-01-17 2004-04-08 The Brigham And Women's Hospital Inc., Boston Rezeptorspezifischer transepithelialer transport von immunogenen
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
AUPO269996A0 (en) * 1996-10-01 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A method of prophylaxis and treatment
EP1118335A1 (fr) * 2000-01-11 2001-07-25 Aventis Behring GmbH Préparation de conjugués pour le traitement des allergies et maladies autoimmunitaires
EP1118334A1 (fr) * 2000-01-11 2001-07-25 Aventis Behring Gesellschaft mit beschränkter Haftung Préparation de conjugués pour le traitement des allergies et maladies autoimmunitaires

Also Published As

Publication number Publication date
WO2004098645A1 (fr) 2004-11-18
CA2524615A1 (fr) 2004-11-18

Similar Documents

Publication Publication Date Title
JP5190698B2 (ja) 糖尿病及びスティフマン症候群の診断及び治療用改良試薬及び方法
US9078843B2 (en) Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
JPH09503387A (ja) クローン化されたグルタミン酸デカルボキシラーゼ
EA036102B1 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
JP3554319B2 (ja) ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
US20150044245A1 (en) Partial mhc constructs and methods of use
US20070129307A1 (en) Insulin epitopes for the treatment of type 1 diabetes
US6207159B1 (en) Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
AU2003232751A1 (en) Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
JP2004532896A (ja) Ｉ型糖尿病の診断及び治療
HUT77484A (hu) Peptidek és ezeket tartalmazó gyógyszerkészítmények
AU690234B2 (en) Peptides and methods against diabetes
US20230181638A1 (en) Immunogenic peptides with new oxidoreductase motifs
US6358751B1 (en) Involvement of autoantigens in cardiac graft rejection
US9617325B2 (en) Treatment of IgE-mediated disease
JP2023525276A (ja) 延長された酸化還元酵素モチーフを有する免疫原性ペプチド
WO2002045735A2 (fr) Compositions et procedes utiles en therapie par avidite
US20030176351A1 (en) Peptides and peptide analogues designed from a diabetes-associated autoantigen, and methods for their use in the treatment and prevention of diabetes
JP2023538002A (ja) 制御性ｔ細胞エピトープ
JP2023508141A (ja) Ｓ－アレスチンペプチドを含む組成物
KR20220030217A (ko) 개선된 백신 제형
JP2023520989A (ja) １型糖尿病の予防および治療に有用なｔレジトープ構築物
US20020187147A1 (en) Antigen specific recombinant MHC class II molecules and methods of use
Christie ISLET PROTEINS INMPLICATED| N PATHOGENESIS OF TYPE
US20030064413A1 (en) Compositions and methods useful in avidity therapy

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period